FDA Determines Regulatory Review Period for Neumega Patent Extension

Summary

The Food and Drug Administration (FDA) has officially confirmed the review period for Neumega, a human biological product, in response to a patent extension application submitted to the U.S. Patent and Trademark Office, as mandated by law.